Revisiting the predictors of a sustained virologic response in the era of direct-acting antiviral therapy for hepatitis C virus

Clinical Infectious Diseases

Volumn 56, Issue 1, 2013, Pages 118-122

  Graham, Camilla S ^a   Beinhardt, Sandra ^a   Rutter, Karoline ^a   Stättermayer, Albert Friedrich ^a   Ferenci, Peter ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

direct acting antivirals; hepatitis C; peginterferon; prediction; ribavirin

Indexed keywords

BOCEPREVIR; DANOPREVIR; FALDAPREVIR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 28B; INTERLEUKIN 8; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MERICITABINE; TELAPREVIR; VIRUS RNA; VITAMIN D;

ALCOHOL ABUSE; ANTIVIRAL THERAPY; ARTICLE; DIABETES MELLITUS; DISEASE SEVERITY; GENETIC ASSOCIATION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INSULIN RESISTANCE; OBESITY; PREDICTIVE VALUE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS LOAD; VITAMIN BLOOD LEVEL;

EID: 84871231459     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis843     Document Type: Article

References (50)

1. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358:958-65.
2. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-82.
3. Poordad F, Bronowicki JP, Gordon SC, et al. Factors that predict response of patients with hepatitis C virus infection to boceprevir. Gastroenterology 2012; 143:608-18.
4. Muir AJ, Bornstein JD, Killenberg PG, Atlantic Coast Hepatitis Treatment Group. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med 2004; 350:2265-71.
5. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment induced viral clearance. Nature 2009; 461:399-401.
6. Ji HF. Vitamin D levels may explain the racial differences in response rates to antiviral therapy for chronic hepatitis C. Hepatology 2011; 54:1489.
7. Ferenci P. Optimal treatment duration for patients with HCV genotype 1 infection. J Viral Hepatitis 2012; 19(suppl 1):7-13.
8. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364:2405-16.
9. Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364:1195-206.
10. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364:2417-28.
11. Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364:1207-17.
12. Cheng WS, Roberts SK, McCaughan G, et al. Low virological response and high relapse rates in hepatitis C genotype 1 patients with advanced fibrosis despite adequate therapeutic dosing. J Hepatol 2010; 53:616-23.
13. Reiberger T, Rutter K, Ferlitsch A, et al. Portal pressure predicts outcome and safety of antiviral therapy in cirrhotic patients with HCV infection. Clin Gastroenterol Hepatol 2011; 9:602-8.
14. Rubbia-Brandt L, Giostra E, Mentha G, Quadri R, Negro F. Expression of liver steatosis in hepatitis C virus infection and pattern of response to alpha-interferon. J Hepatol 2001; 35:307.
15. Bressler BL, Guindi M, Tomlinson G, et al. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology 2003; 38:639-44.
16. Romero-Gomez M, Del Mar Viloria M, Andrade RJ, et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005; 128: 636-41.
17. Moucari R, Forestier N, Larrey D, et al. Danoprevir, an HCV NS3/4A protease inhibitor, improves insulin sensitivity in patients with genotype 1 chronic hepatitis C. Gut 2010; 59:1694-8.
18. Marcellin M, Forns X, Goeser T, et al. Telaprevir administered every 8 or 12 hours in combination with ribavirin and either peginterferon alfa-2a or alfa-2b: results from a randomised trial in treatment-naive patients with genotype 1 chronic hepatitis C. Gastroenterology 2011; 140:459-68.
19. Serfaty L, Forns X, Goeser T, et al. Insulin resistance and response to telaprevir plus peginterferon alfa and ribavirin in treatment-naive, genotype 1 HCV patients. Gut 2012; 61:1473-80.
20. Moucari R, Asselah T, Cazals-Hatem D, et al. Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterology 2008; 134:416-23.
21. Arase Y, Suzuki F, Suzuki Y, et al. Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C. Hepatology 2009; 49:739-44.
22. McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009; 361:580-93.
23. Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461:798-801.
24. Rauch A, Kutalik Z, Descombes P, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genomewide association study. Gastroenterology 2010; 138:1338-45.
25. McCarthy JJ, Li JH, Thompson A, et al. Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology 2010; 138:2307-14.
26. Thompson AJ, McHutchison JG. Will IL28B polymorphism remain relevant in the era of direct acting antiviral agents for HCV? Hepatology 2012; 56:383-81.
27. Poordad F, Bronowicki JP, Gordon SC, et al. IL28b polymorphism predicts virological response in patients with chronic hepatitis C genotype 1 treated with boceprevir (BOC) combination therapy. J Hepatol 2011; 54:S12.
28. Sulkowski MS, Ceasu E, Asselah T, et al. SILEN-C1: Sustained virologic response (SVR) and safety of BI201335 combined with peginterferon alfa-2a and ribavirin (P/R) in treatment-naive patients with chronic genotype 1 HCV infection. J Hepatol 2011; 54(suppl 1):S27.
29. Fried M, Buti M, Dore GJ, et al. TMC435 in combination with peginterferon and ribavirin in treatment-naive HCV genotype 1 patients: final analysis of the PILLAR phase IIb study. Hepatology 2011; 54 (suppl 1):LB5.
30. Jacobson IM, Catlett I, Marcellin P, et al. Telaprevir substantially improves SVR rates across all IL28B genotypes in the ADVANCE trial. J Hepatol 2011; 54:S1369.
31. Beinhardt S, Staettermayer AF, Rutter K, et al. Treatment of chronic hepatitis C GT 1 patients at an academic center in Europe involved in prospective controlled trials: is there a selection bias? Hepatology 2012; 55:30-8.
32. Chu TW, Kulkarni R, Gane EJ, et al. Effect of IL28B genotype on early viral kinetics during interferon-free treatment of patients with chronic hepatitis C. Gastroenterology 2012; 142:790-5.
33. Zeuzem S, Asselah T, Angus P, et al. Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection. Gastroenterology 2011; 141:2047-55.
34. Naggie S, Anu Osinusi A, Katsounas A, et al. Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28B-unfavorable genotype patients: impaired viral kinetics and therapeutic response. Hepatology 2012; 56:444-54.
35. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140:346-55.
36. Jensen DM, Morgan TR, Marcellin P, et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon α-2a (40KD)/ribavirin therapy. Hepatology 2006; 43:954-60.
37. Chayama K, Takahashi S, Toyota J, et al. Dual therapy with the NS5A inhibitor BMS-790052 and the NS3 protease inhibitor BMS-650032 in HCV genotype 1b-infected null responders. Hepatology 2011; 55:742-8.
38. Lok AS, Gardiner DF, Lawitz E, et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med 2012; 366:216-24.
39. Neumann AU, Lam NP, Dahari H, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998; 282:103-7.
40. Zeuzem S, Schmidt JM, Lee JH, Ruster B, Roth WK. Effect of interferon alfa on the dynamics of hepatitis C virus turnover in vivo. Hepatology 1996; 23:366-71.
41. Guedj J, Perelson AS. Second-phase hepatitis C virus RNA decline during telaprevir-based therapy increases with drug effectiveness: implications for treatment duration. Hepatology 2011; 53:1801-8.
42. Halfon P, Locarnini S. Hepatitis C virus resistance to protease inhibitors. J Hepatol 2011; 55:192-206.
43. Jessner W, Gschwantler M, Steindl-Munda P, et al. Primary interferon resistance and treatment response in chronic hepatitis C infection: a pilot study. Lancet 2001; 358:1241-2.
44. Ferenci P, Fried MW, Shiffman ML, et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a/ribavirin. J Hepatol 2005; 43:425-33.
45. Stättermayer AF, Stauber R, Hofer H, et al. Impact of the IL28Bgenotype on early and sustained virologic response in treatment-naive patients with chronic hepatitis C treated with peg-interferon-α2a and ribavirin. Clin Gastroenterol Hepatol 2011; 9:344-50.
46. Fried MW, Hadziyannis SJ, Shiffman ML, Messinger D, Zeuzem S. Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection. J Hepatol 2011; 55:69-75.
47. Ferenci P, Laferl H, Scherzer TM, et al. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. Gastroenterology 2008; 135:451-8.
48. Ferenci P. Optimal treatment duration for patients with HCV genotype 1 Infection. J Viral Hepat 2012; 19(suppl 1):7-13.
49. Wedemeyer H, Jensen DM, Godofsky E, et al., on behalf of the Definitions/Nomenclature Working Group of the HCV DrAG (HCV Drug Development Advisory Group), under the auspices of the Forum for Collaborative HIV Research. Recommendations for standardized nomenclature and definitions of viral response in trials of HCV investigational agents. Hepatology 2012. [Epub ahead of print]. doi:10.1002/hep.2588.
50. McHutchison JG, Manns M, Patel K, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002; 123:1061-9.